New R&D agreement to expand Ziopharm’s TCR-T Program

New R&D agreement to expand Ziopharm's TCR-T Program Ziopharm Oncology, an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy, has concluded a new R&D agreement with MD Anderson Cancer Center. This agreement is related…..

Fourth FDA approval for Vertex’s cystic fibrosis medicines

Fourth FDA approval for Vertex's cystic fibrosis medicines The FDA has approved Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of…..

Chiffres clés de la recherche clinique en France

A l’occasion de la 7ème journée de la recherche clinique, l’AFCROs, qui regroupe 75 sociétés-membres représentant environ 70% de l’activité dans le domaine de la recherche clinique et épidémiologique, a présenté les chiffres clés de la recherche clinique en France. Cet outil réalisé par les groupes de travail de l’association…..